South Korean biopharmaceutical firm Samsung Bioepis Co. said Friday it has won approval from European authorities for the sale of its biosimilar drug Imraldi.
The European Commission accepted Samsung Bioepis' application to sell the biosimilar referencing AbbVie Inc.'s Humira, the company said in a regulatory filing. The drug treats various diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, and Crohn’s disease.
With the approval, Imraldi can be sold in 28 EU member states as well as Norway, Iceland and Liechtenstein, the company said.
|Screen grab of Samsung Bioepsis' website|
With the marketing authorization of Imraldi, Samsung BIoepis became the first player to receive European approval for biosimilars referencing all three blockbuster immunology medicines in Europe.
In 2016, Samsung Bioepis won the EC marketing authorization for Renflexis, a biosimilar referencing Janssen Biotech, Inc.'s blockbuster immunology medicine Remicade and BBenepali, a biosimilar referencing Enbrel.
"It is meaningful that we became the industry's first to obtain European approval for a third inhibitor," said the company.
The approval comes two months after the European Medicines Agency adopted a positive opinion on Imraldi.
Samsung Bioepis was established in 2012 in a joint venture between Samsung Biologics and Biogen Inc. Samsung BioLogics is a biopharmaceutical unit of South Korea's top conglomerate Samsung Group.
The market for biosimilars -- which are almost an identical copy of an original or generic drugs -- have grown in recent years as they are provided to customers at discounts. Biosimilars are officially approved copycat medicines developed after patents for the original biopharmaceuticals expire. (Yonhap)